What is BPC-157 (Oral)?
Oral BPC-157 formulation discussed for GI-first protocols; evidence remains limited.
Research Indications
Demonstrated acceleration of wound healing and soft tissue repair in research
Research shows beneficial effects on intestinal lining and GI function
Associated with reduced joint inflammation and improved mobility
May support faster recovery from muscle strains and exercise stress
Research Protocols
These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Starting Dose | 100 mcg | Once daily | Subcutaneous injection |
| Standard Dose | 250 mcg | Once daily | Subcutaneous injection |
Peptide & Drug Interactions
Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.
How to Reconstitute & Inject
Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.
- 1
Remove BPC-157 (Oral) vial from refrigeration and allow to reach room temperature (15–20 minutes)
- 2
Clean vial top with alcohol swab and allow to air dry completely
- 3
Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)
- 4
Inject BAC water slowly down the side of the vial — do not aim directly at the powder
- 5
Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide
- 6
Allow 2–3 minutes for full dissolution — solution should be clear and colorless
- 7
Draw calculated dose into an insulin syringe for subcutaneous injection
- 8
Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy
- 9
Store reconstituted solution refrigerated (2–8°C) and use within 28 days
What to Expect
Week 1–2
Initial anti-inflammatory effects begin. Reduced pain and swelling in target area.
Week 2–4
Improved tissue mobility and reduced discomfort. Early healing acceleration.
Week 4–8
Significant recovery milestones. Stronger tissue repair and functional improvement.
Week 8–12
Near-complete healing in many cases. Improved strength and tissue integrity.
Side Effects & Safety
- Generally well-tolerated in research settings
- Mild nausea with higher doses
- Injection site redness or discomfort
- Rare: Dizziness or lightheadedness
- Potential effect on blood pressure (monitor if hypertensive)
BPC-157 (Oral) is banned from 503A compounding pharmacies. Only available through 503B outsourcing facilities or for research use.
FDA Status & Regulatory Info
Oral BPC-157 formulation discussed for GI-first protocols; evidence remains limited.
Frequently Asked Questions
Research References
External links for education only. We do not control third-party content.
Community-reported data
The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.
Community Intelligence
What 26 users report
Positive 97% · Neutral 3% · Negative 0%
Most reported benefits
Most reported side effects
Dose distribution
Median: 600–1000 mcg · Most common: 1000–2000 mcg
Commonly stacked with
How repeat users are trending
Among repeat reporters, 90% said they felt similar to their last entry, 10% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 215 days · Based on 20 repeat reporters
Share Your Experience
Rate BPC-157 (Oral) in the PeptIQ app and help the community make informed decisions.
Research purposes only
This page is for educational reference. It is not medical or legal advice. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.